Advertisement

Topics

A-Viral ASA Company Profile

01:50 EDT 20th September 2017 | BioPortfolio

The company was formally registered in 1986, but there were little activity until 1997. Then the company acquired its first patent application. The company had its first major public offering in the fall of 1998, at the same time when Einar Stokke became CEO. Since then more than 7 million Euros has been used for research, by far the major part of it on AV 1101.Numerous laboratory tests took place at the National Institute of Public Health in Oslo from 1998. Later laboratory testing has shifted towards our research partner, CLB-Sanquin in Amsterdam , which has been the centre for our lab. research for several years now.
Through studies of OxyPhenylButazone (OBP) AV 1101 was discovered. AV 1101 is 4-Hydroxy-OxyPhenylButazone. The chemical itself is known through literature only as a metabolite from PhenylButazone (PB), and A-Viral has a patent application for AV 1101 and many closely related forms for all therapeutic use in humans and animals. AV 1101 has recently acquired a patent grant in USA for use against inflammatory and autoimmune diseases.
(read more: Patents)
In 2001 A-Viral started to have its lab research done at CLB – Sanquin. A research group under professor Lucien Aarden (specialist in cellular immunology) started the work to find the basic functions of AV 1101. They perform a lot of testing with AV 1101, and measures how various blood cells react to AV 1101 under different conditions, measuring cell activation, proliferation and cytokine production. In the beginning they also tested on how HIV would propagate in the presence of AV 1101. They have also checked out metabolites of and conjugates from AV 1101, and tested which are still active. Assays for measuring AV 1101 in blood have been developed. New related substances are synthesized and tested, etc. This research is the basis for our understanding of AV 1101, and it is the platform on which we build our clinical research. And our team at CLB does additional analysis with blood samples from our clinical studies, retrieving important information about the function of AV 1101

Location

Postboks 1780
Vika
Oslo
122
Norway

Contact

Phone: 47 23118953
Fax: 47 23118959
Email: bjorn.ivar@gmail.com


News Articles [410 Associated News Articles listed on BioPortfolio]

Rebound in HIV Viral Load Possible in Pregnant Women Near Delivery

HIV-infected women who achieve viral suppression with combination antiretroviral therapy (CART) during pregnancy may experience viral load rebound around the time of delivery, report researchers from ...

Immunexpress Release: Four-Biomarker Signature Differentiates Viral And Non-Viral Causes Of Systemic Inflammation

  Life Sciences Jobs   ...

Financial incentives enhance viral suppression among HIV-positive persons in the US

(Columbia University's Mailman School of Public Health) The use of gift cards significantly increased viral suppression and clinic attendance among HIV-positive patients. Findings showed that there wa...

Servier, Transgene partner to apply viral vectorization technology

Servier and Transgene, a biotechnology company that designs and develops immunotherapies based on viral vectors, announced the signature of a research agreement on the application of viral vectorizati...

Study Finds White Children Receive Antibiotics for Viral Illness at a Higher Rate

White children with viral diagnoses treated in pediatric emergency departments were up to twice as likely to receive antibiotics compared to minority children, according to a study published in Pediat...

Single HIV Value Overestimates Viral Suppression

A single HIV viral load assessment may be insufficient to limit infection transmission, researchers say. Medscape Medical News

Live and let die: ZBP1 senses viral and cellular RNAs to trigger necroptosis

Necroptosis is a programmed form of inflammatory cell death involved in various pathologies, such as viral infections. In two new papers published in The EMBO Journal and EMBO Reports, Z-DNA binding p...

When to Skip Cultures in Kids With Pharyngitis

Does the number of overt viral symptoms offer a reliable way to distinguish viral from group A strep pharyngitis? Medscape Pediatrics

Drugs and Medications [19 Associated Drugs and Medications listed on BioPortfolio]

Zovirax [BTA PHARMACEUTICALS INC]

ZOVIRAX (acyclovir) Ointment 5%

Zovirax [BTA PHARMACEUTICALS INC]

ZOVIRAX (acyclovir) Cream 5%USE ONLY FOR COLD SORES

Denavir [New American Therapeutics, Inc]

Denavir BRAND OF penciclovir cream, 1% For Dermatologic Use Only Rx only

Denavir [Novartis Consumer Health, Inc.]

Denavir

Denavir [Physicians Total Care, Inc.]

Denavir

PubMed Articles [1123 Associated PubMed Articles listed on BioPortfolio]

Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control.

We evaluated the fraction of variation in HIV-1 set point viral load attributable to viral or human genetic factors by using joint host/pathogen genetic data from 541 HIV infected individuals. We show...

Impact of viral hepatitis etiology on survival outcomes in hepatocellular carcinoma: a large multi-center cohort study.

While HBV and HCV are risk factors for HCC, uncertainty exists as to whether these viral infections have prognostic significance in HCC. Thus, we compared the overall survival of patients with HBV, HC...

Viral Features and Testing for Streptococcal Pharyngitis.

The Infectious Diseases Society of America recommends that clinicians forego testing for group A Streptococcal (GAS) pharyngitis in patients with clinical features of viral illness. The prevalence of ...

Viral-specific T-cell response in hemorrhagic cystitis after haploidentical donor stem cell transplantation.

Viral hemorrhagic cystitis (HC) after hematopoietic stem cell transplantation (HSCT) can be devastating. Standard treatment modalities have not been well established, but immune reconstitution may be ...

Origins and Challenges of Viral Dark Matter.

The accurate classification of viral dark matter - metagenomic sequences that originate from viruses but do not align to any reference virus sequences - is one of the major obstacles in comprehensivel...

Clinical Trials [976 Associated Clinical Trials listed on BioPortfolio]

Third Party Anti-Viral Cytotoxic T-Cells

The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infect...

FST-100 in the Treatment of Acute Viral Conjunctivitis

This randomized, double masked, multi-center study is being conducted to support the safety and efficacy of FST-100 for the treatment of acute viral conjunctivitis. The study intends to sh...

Intensive Viral Dynamics Substudy of A5248

The HIV integrase inhibitor, raltegravir (RAL), which was recently approved by the FDA, has been shown in several trials to be highly effective. The main study will estimate the viral load...

Use of TREM-1 Protein to Differentiate Viral and Bacterial Pneumonias in Intubated Children

The purpose of this study is to determine whether a protein called TREM-1 can be used to differentiate viral and bacterial pneumonias in children who are on ventilator support. We propose ...

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

The purpose of this study is to see if adding 1 drug to an anti-HIV drug combination early in treatment against HIV can lower the viral load (amount of HIV in the blood) to a level so low ...

Companies [208 Associated Companies listed on BioPortfolio]

Virus Detection & Diagnostics Virinova

Our unique and proprietory diagnostic technology enables the detection and quantification of viruses without the use of PCR or antibodies - Direct detection of viruses and viral particles - F...

Brickfish®

Brickfish® is the performance-based Cost Per Engagement® (CPE®) social media solution that has generated 300 million consumer engagements and conversations for advertisin...

Cavit Sciences

Cavit Sciences, Inc. (“Cavit”) is a biotechnology company engaged in developing treatments of cancer and viral infections. Our strategy is to develop and commercialize intellectual property right...

NanoViricides, Inc.

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricid...

Molecular Medicine BioServices (

Molecular Medicine BioServices (MMB) is dedicated to providing a variety of development, manufacturing, and ancillary services for the viral vaccine and viral therapeutic marketplace. In this exciting...

More Information about "A-Viral ASA" on BioPortfolio

We have published hundreds of A-Viral ASA news stories on BioPortfolio along with dozens of A-Viral ASA Clinical Trials and PubMed Articles about A-Viral ASA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of A-Viral ASA Companies in our database. You can also find out about relevant A-Viral ASA Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...


Corporate Database Quicklinks



Searches Linking to this Company Record